EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer

Lakshmi Sandhya, Nirmala Devi Sreenivasan, Luxitaa Goenka, Biswajit Dubashi iD, Smita Kayal, Manikandan Solaiappan, Ramkumar Govindarajalou iD, Harichandrakumar Kt, Prasanth Ganesan iD

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.22.01997 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Lakshmi Sandhya und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. Hauptthemen laut MEDLINE: Anorexia, Lung Neoplasms. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Anorexia occurs in 30%-80% of patients with advanced malignancies, which may be worsened with chemotherapy. This trial assessed the efficacy of olanzapine in stimulating appetite and improving weight gain in patients receiving chemotherapy. METHODS Adults (≥18 years) with untreated, locally advanced, or metastatic gastric, hepatopancreaticobiliary (HPB), and lung cancers were randomly assigned (double-blind) to receive olanzapine (2.5 mg once a day for 12 weeks) or placebo along with chemotherapy. Both groups received standard nutritional assessment and dietary advice. The primary outcomes were the proportion of patients with weight gain > 5% and the improvement in appetite (assessed by the visual analog scale [VAS] and the Functional Assessment of Chronic Illness Therapy system of Quality-of-Life questionnaires Anorexia Cachexia subscale [FAACT ACS]). Secondary end points were change in nutritional status, quality of life (QOL), and chemotherapy toxicity. RESULTS We enrolled 124 patients (olanzapine, 63 and placebo, 61) with a median age of 55 years (18-78 years), of whom 112 (olanzapine, 58 and placebo, 54) were analyzable. The majority (n = 99, 80%) had metastatic cancer (gastric [n = 68, 55%] > lung [n = 43, 35%] > HPB [n = 13, 10%]). The olanzapine arm had a greater proportion of patients with a weight gain of > 5% (35 of 58 [60%] v 5 of 54 [9%], P < .001) and improvement in appetite by VAS (25 of 58 [43%] v 7 of 54 [13%], P < .001) and by FAACT ACS (scores ≥37:13 of 58 [22%] v 2 of 54 [4%], P = .004). Patients on olanzapine had better QOL, nutritional status, and lesser chemotoxicity. Side effects attributable to olanzapine were minimal. CONCLUSION Low-dose, daily olanzapine is a simple, inexpensive, well-tolerated intervention that significantly improves appetite and weight gain in newly diagnosed patients on chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnorexiaLung NeoplasmsAdultHumansMiddle AgedOlanzapineQuality of LifeDouble-Blind MethodWeight Gain

Substanzen

Olanzapine

Autor:innen und Institutionen

  • Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
  • Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
  • Radiodiagnosis, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
  • Biostatistics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.

ORCID-Profile: Biswajit Dubashi, Ramkumar Govindarajalou, Prasanth Ganesan

Zitieren

APA

Sandhya, L., Devi Sreenivasan, N., Goenka, L., Dubashi, B., Kayal, S., Solaiappan, M., Govindarajalou, R., Kt, H., & Ganesan, P. (2023). Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.01997

Vancouver

Sandhya L, Devi Sreenivasan N, Goenka L, Dubashi B, Kayal S, Solaiappan M, et al. Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.01997

BibTeX
@article{Sandhya2023,
  author = {Sandhya, Lakshmi and Devi Sreenivasan, Nirmala and Goenka, Luxitaa and Dubashi, Biswajit and Kayal, Smita and Solaiappan, Manikandan and Govindarajalou, Ramkumar and Kt, Harichandrakumar and Ganesan, Prasanth},
  title = {Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.22.01997}
}
Kostenlos starten →